巴郡上季淨利潤冠絕全球 工行(01398.HK)排第五
據FactSet Research統計顯示,股神巴菲特旗下投資旗艦巴郡(BRK.A.US)以第二財季262.95億美元淨利潤,成為今年第二季度全球最賺錢企業,主要受其持有的蘋果公司等股票賬面收益增加所推動。
統計列出今年第二季全球約4.4萬家上市企業中賺錢的100家,軟銀集團及蘋果公司分別排名第2位及第3位。香港上市公司方面,工商銀行(01398.HK)以淨利潤90.7億美元,位列第5位;阿里巴巴(09988.HK)排第9位,淨利潤67.1億美元;京東(09618.HK)排第41位,淨利潤23.2億美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.